This single-center, open-label study will investigate the pharmacokinetics and elimination of a radiolabelled dose of RO4602522 in healthy male volunteers. The healthy male volunteers will receive a single oral dose of RO4602522.
Study Type
INTERVENTIONAL
Allocation
NON_RANDOMIZED
Masking
NONE
Enrollment
6
Single radiolabeled dose
Unnamed facility
Zuidlaren, Netherlands
Pharmacokinetics: Elimination of RO4602522: urine/feces concentration
Time frame: Predose, Day 1, 2 and 3
Pharmacokinetics: Plasma concentration of RO4602522/metabolite
Time frame: Predose, Day 1, 2 and 3
Pharmacokinetics: Metabolic profile of RO4602522: plasma/urine/feces concentration
Time frame: Predose, Day 1, 2 and 3
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.